Perspectives from Christian Angermayer, investor and founder in psychedelics
Business Trip, a podcast about psychedelic startups
Welcome back to Business Trip, a podcast about psychedelic startups! 🍄
In this week’s episode, we chat with Christian Angermayer. Christian co-founded atai Life Sciences and was an early investor in Compass Pathways -- two of the first companies commercializing psychedelic medicine. Christian also launched a fund dedicated to mental and neurological health called re:Mind, is an investor through his family office Apeiron, and co-founded two longevity biotech companies.
In this episode, we discuss:
What the psychedelic field will look like in the next couple years
His views on patents, ketamine telehealth, & 1st vs. 2nd gen psychedelics
Fundraising tips for founders
How he generates investment ideas
Learnings from his own psychedelic experiences
Listen to the episode here, on Spotify or Apple Podcasts.
When you’re done listening, tweet at us @businesstripfm to share your thoughts!
About Us
Business Trip is a podcast about psychedelic startups. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.
Business Trip is produced by Greg Kubin and Matias Serebrinsky — we’re partners at PsyMed Ventures, advocates of the healing powers of psychedelic medicine.
Thanks for listening,
💖 Know someone who would enjoy Business Trip?